CohBar Inc is focused on mitochondrially-derived peptides for the development of therapeutics for age-related diseases.In October 2021, CohBar, Inc. announced a proposed underwritten public offering of shares and warrants to purchase common stock. Later that month, the company priced an underwritten public offering of 20,833,334 shares at $0.72 per share to raise $15.0 million.In August 2020, the company completed a public offering to support its clinical and preclinical programs and raised $15 million capital and added to biotech focused institutional investors. By August 2020, the company joined the Russell 2000 and 3000 Indexes. Later that month, the company proposed an underwritten public offering of units consisting of one share of the company's common stock and one warrant to purchase 0.75 of a share of common stock and would be exercisable for five years from the closing date of the offering. Also, at that time, the company expected to grant the underwriters